ArticleDrugs - real world outcomes2026
Age and Gender Heterogeneity in Adverse Drug Reactions Associated with Hemp Use: Evidence from the FDA Pharmacovigilance Data in the Last Two Decades.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHemp-derived products are increasingly used for medical and wellness purposes following legalization, yet systematic safety data remain limited.
objectiveWe aimed to identify the most common adverse drug reactions associated with hemp use and to evaluate age- and gender-specific differences in risk.
methodsWe analyzed adverse event reports submitted to the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 1 January, 2004 to 30 June, 2025. Reporting odds ratios (RORs) with 95% confidence intervals (CIs) for hemp-associated adverse drug reactions were calculated.
resultsAmong 19,345,024 FAERS reports, 1712 involved hemp products. The most frequently reported adverse drug reactions included fatigue (180), nausea (152), diarrhea (138), headache (126), dizziness (119), pain (119), anxiety (115), dyspnea (86), arthralgia (82), vomiting (82), insomnia (79), depression (76), weight decreased (70), asthenia (68), feeling abnormal (68), fall (67), decreased appetite (60), pain in extremity (60), seizure (60), and somnolence (58). Seizures (ROR 6.76, 95% CI 5.22-8.75), anxiety (ROR 5.15, 95% CI 4.26-6.22), and depression (ROR 4.13, 95% CI 3.28-5.19) were most strongly associated with hemp. Older adults exhibited higher RORs for diarrhea, dizziness, arthralgia, asthenia, fall, decreased appetite, and pain in extremity, whereas younger adults showed stronger associations with fatigue, nausea, headache, pain, anxiety, dyspnea, vomiting, insomnia, depression, weight decreased, feeling abnormal, seizure, and somnolence. Women demonstrated higher RORs across nearly all adverse drug reactions except seizures, which were more strongly associated with men.
conclusionsUse of hemp-derived products are associated with adverse drug reactions, including serious neurological and psychiatric events, with marked heterogeneity by age and gender.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.